Comparison between the clinical efficacy of platelet concentrates, derived from buffy coat and apheresis in tumor patients

Hao,Baolan; Wang,Yan; Zhou,Jian; Shao,Shujun; Dong,Xiaofeng

doi:10.3892/ol.2017.6270

Comparison between the clinical efficacy of platelet concentrates, derived from buffy coat and apheresis in tumor patients

Authors:
- Baolan Hao
- Yan Wang
- Jian Zhou
- Shujun Shao
- Xiaofeng Dong
View Affiliations

Affiliations: Department of Blood Transfusion, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan 450008, P.R. China
Published online on: May 26, 2017 https://doi.org/10.3892/ol.2017.6270
Pages: 1445-1448
Copyright: © Hao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to evaluate the clinical efficacy between manual buffy coat-derived platelet concentrates (PCs) and automated apheresis platelet concentrates (APCs) in terms of their therapeutic effects. The corrected count increment (CCI) was calculated according to detected differences in platelet concentration in patients who underwent transfusion of APCs, prepared by an automated system (group I, 72 cases) or PCs derived from buffy coat by manual method (group II, 83 cases). The clinical efficacy was assessed in terms of the CCI and clinical symptoms. The platelet contents of all the PCs were detected before transfusion. The mean 1 h CCI was 13.56±4.45 and 24 h CCI was 8.67±4.21 in group I, while the mean 1 h CCI was 15.83±4.65 and 24 h CCI was 9.57±3.36 in group II. The effective rates judged by CCI for groups I and II were 53 and 64%, respectively, and those judged by clinical symptoms were 67 and 60%, respectively. In conclusion, the clinical effectiveness of manual PCs was similar to that for APCs; thus, it could be utilized for clinical use.

View Figures

View References

1	Fletcher CH, DomBourian MG and Millward PA: Platelet transfusion for patients with cancer. Cancer Control. 22:47–51. 2015.PubMed/NCBI
2	Kumar A, Mhaskar R, Grossman BJ, Kaufman RM, Tobian AA, Kleinman S, Gernsheimer T, Tinmouth AT and Djulbegovic B: AABB Platelet Transfusion Guidelines Panel: Platelet transfusion: a systematic review of the clinical evidence. Transfusion. 55:1116–1127. 2015. View Article : Google Scholar : PubMed/NCBI
3	Schrezenmeier H and Seifried E: Buffy-coat-derived pooledplatelet concentrates and apheresis platelet concentrates: which product type should be preferred? Vox Sang. 99:1–15. 2010. View Article : Google Scholar : PubMed/NCBI
4	van der Meer PF: Platelet concentrates, from whole blood or collected by apheresis? Transfus Apher Sci. 48:129–131. 2013. View Article : Google Scholar : PubMed/NCBI
5	Holbro A, Infanti L, Sigle J and Buser A: Platelet transfusion: Basic aspects. Swiss Med Wkly. 143:w138852013.PubMed/NCBI
6	Novotny VM: Prevention and management of platelet transfusion refractoriness. Vox Sang. 76:1–13. 1999. View Article : Google Scholar : PubMed/NCBI
7	Rebulla P: Refractoriness to platelet transfusion. Curr Opin Hematol. 9:516–520. 2002. View Article : Google Scholar : PubMed/NCBI
8	Pavenski K, Freedman J and Semple JW: HLA alloimmunization against platelet transfusions: Pathophysiology, significance, prevention and management. Tissue Antigens. 79:237–245. 2012. View Article : Google Scholar : PubMed/NCBI
9	Xia WJ, Ye X, Deng J, Chen YK, Xu XZ, Ding HQ, Luo GP and Fu YS: Study of the platelet GP specific antibodies and HLA antibodies expression in platelet transfusion refractoriness patients. Zhonghua Xue Ye Xue Za Zhi. 31:594–598. 2010.(In Chinese). PubMed/NCBI
10	Eisenberg S: Refractory response to platelet transfusion therapy. J Infus Nurs. 33:89–97. 2010. View Article : Google Scholar : PubMed/NCBI
11	Hod E and Schwartz J: Platelet transfusion refractoriness. Br J Haematol. 142:348–360. 2008. View Article : Google Scholar : PubMed/NCBI
12	Shastry S and Chaudhary R: Clinical factors influencing corrected count increment. Transfus Apheresis Sci. 47:327–330. 2012. View Article : Google Scholar
13	Böck M, Rahrig S, Kunz D, Lutze G and Heim MU: Platelet concentrates derived from buffy coat and apheresis: Biochemical and functional differences. Transfus Med. 12:317–324. 2002. View Article : Google Scholar : PubMed/NCBI
14	Zebrowska A, Lipska A, Rogowska A, Bujno M, Nedzi M and Radziwon P: Quality of buffy-coat-derived platelet concentrates prepared using automated system terumo automated centrifuge and separator integration (TACSI). Pol Merkur Lekarski. 30:191–194. 2011.(In Polish). PubMed/NCBI
15	Yang M, Luo H, Shu B, An BQ, Xia SQ and Wang ML: Analysis on effectiveness of platelet transfusion in 1786 patients. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 21:1038–1041. 2013.(In Chinese). PubMed/NCBI
16	Kirkley SA and Blumberg N: Use of single donor platelets. Blood Rev. 8:142–147. 1994. View Article : Google Scholar : PubMed/NCBI
17	Cid J, Ramiro L, Escoda L and Llorente A: Efficacy of transfusion of platelet concentrates obtained by manual pooling or by semiautomated pooling of buffy-coats: a retrospective analysis of count increment, corrected count increment and transfusion interval. Vox Sang. 96:29–33. 2009. View Article : Google Scholar : PubMed/NCBI
18	Feng ML, Liu DZ, Shen W, Wang JL, Guo ZH, Zhang X, Du KM, Qian KC and Zhao TM: Establishment of an HPA-1- to −16-typed platelet donor registry in China. Transfus Med. 16:369–374. 2006. View Article : Google Scholar : PubMed/NCBI
19	Yuan Q, Chen X, Cheng L, Zhou CH, Fu XM, Li YP, Wang NH and Wang L: Prevention of platelet transfusion refractoriness and HLA alloimmunization by leukocyte filtered platelet transfusion: A meta analysis. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 33:412–420. 2011.(In Chinese). PubMed/NCBI